euro adhoc: Intercell AG / other / US Defense Logistics Agency announces plans to enter into supply contract to purchase Japanese Encephalitis vaccine

» Request for Proposal (RFP) aiming at exclusive, multiyear contract for
Japanese Encephalitis (JE) vaccine

» Intercell in a unique position to respond to strategic needs of US armed
forces (E)=

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

21.08.2008

Vienna (Austria), August 21, 2008 - Intercell AG (VSE: ICLL) announced that the
Defense Logistics Agency (DLA), United States Department of Defense, has posted
today a Request for Proposal (RFP) for purchase of Japanese Encephalitis (JE)
vaccine. As JE is a serious and growing public health threat in Asia, the DLA
intends to enter into a contract to purchase supplies of JE vaccine for use with
military personnel who are deployed to affected countries.

The major details of this RFP are as follows:

» Exclusive contract to supply DLA with their requirements for JE vaccine

» Multiyear contract, with annual options to facilitate price and quantity
modifications

» Duration of contract will be 5 years, at minimum

Intercell has already been in close contact with the DLA regarding this RFP and
believes one reason for this proposed contract at this time is the pending
Biological License Application (BLA) with the US Food and Drug Administration
(FDA) for Intercell´s JE vaccine. Intercell submitted the BLA for its JE vaccine
in December 2007 and anticipates FDA approval and subsequent first sales to the
military markets in the next few months.

"We are pleased that the DLA has announced this RFP to establish a contract for
supply of JE vaccine," stated Gerd Zettlmeissl, Chief Executive Officer of
Intercell. "Intercell´s JE vaccine was developed in collaboration with the
Walter Reed Army Institute (US Department of Defense) and we look forward to
continuing this valued relationship by securing a long-term, exclusive contract
for supply of the vaccine for use in the military´s JE immunization program.
Intercell plans to respond to this RFP in a timely manner and we are optimistic
that we can successfully close a contract in due time."

Japanese encephalitis, a mosquito-borne flaviviral infection, remains virulent
in Asia and has recently spread to countries not previously infected. Hence, the
virus is a constant health threat to millions of civilian travelers and military
personnel visiting or being deployed to affected countries, including China and
India. There is no treatment for JE, so vaccination is the primary
countermeasure against this disease.

Further inquiry note:
Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-303
[email protected]

end of announcement euro adhoc
--------------------------------------------------------------------------------

emitter: Intercell AG
Campus Vienna Biocenter 6
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: [email protected]
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime, ATX
stockmarkets: official market: Wiener Börse AG
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB

print